InvestorsHub Logo
Followers 63
Posts 7608
Boards Moderated 1
Alias Born 01/02/2003

Re: Chromosome post# 426532

Monday, 07/08/2024 9:39:34 AM

Monday, July 08, 2024 9:39:34 AM

Post# of 429302
Chromosome..."Terms of the agreement( i.e. in 2015) include up-front and milestone payments to Amarin of up to $169.0 million, including a non-refundable $15.0 million up-front payment and development, regulatory and sales-based milestone payments of up to an additional $154.0 million. Eddingpharm will also pay Amarin tiered double-digit percentage royalties on net sales of Vascepa in the territory escalating to the high teens."

With the anticipated large volume of Vaskapa sales in China, the sales base volume should reach $150 million briskly.

As J.T. said..."Vascepa is a volume play...not a price play."
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News